
This listing of claims will replace all prior versions, and listings, of claims in the application:

## **Listing of Claims:**



- N-1-[(4-chlorophenyl)]-N-2-[(4-(2-dimethylaminomethylimidazol-1-yl)-phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
- N-1-[(4-ethynylphenyl)]-N-2-[(4-(2-dimethylaminomethyl-imidazol-1-yl)-phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
- N-1-[(4-chlorophenyl)]-N-2-[(2-fluoro-4-(2-dimethylaminomethyl-imidazol-1-yl)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
- N-1-[(4-ethynylphenyl)]-N-2-[(2-fluoro-4-(2-dimethylamino-methylimidazol-1-yl)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
- N-1-[(4-chlorophenyl)]-N-2-[(4-(N,N-dimethylamidino)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
- N-1-[(4-ethynylphenyl)]-N-2-[(4-(*N*,*N*-dimethylamidino)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
- N-1-[(4-chlorophenyl)]-N-2-[(2-fluoro-4-(*N*,*N*-dimethylamidino)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
- N-1-[(4-ethynylphenyl)]-N-2-[(2-fluoro-4-(*N*,*N*-dimethylamidino)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
- N-1-[(4-chlorophenyl)]-N-2-[(4-(1-methyl-4,5-dihydro-1*H*-imidazol-2-yl)-phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
- N-1-[(4-chlorophenyl)]-N-2-[(2-fluoro-4-(1-methyl-4,5-dihydro-1*H*-imidazol-2-yl)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
- N-1-[(4-ethynylphenyl)]-N-2-[(4-(1-methyl-4,5-dihydro-1*H*-imidazol-2-yl)-phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
- N-1-[(4-ethynylphenyl)]-N-2-[(2-fluoro-4-(1-methyl-4,5-dihydro-1*H*-imidazol-2-yl)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
- and or pharmaceutically usable derivatives, solvates, salts and or stereoisomers thereof, including mixtures thereof in all ratios.
- 9. (Currently Amended) Process for the preparation of compounds of the formula I

in which

R denotes Hal,  $-C \equiv C-H$ ,  $-C \equiv C-A$  or OA,

R<sup>1</sup> denotes H, =O, Hal, A, OH, OA, A-COO-, Ph- $(CH_2)_n$ -COO-, cycloalkyl- $(CH_2)_n$ -COO-, A-CONH-, A-CONA-, Ph-CONA-, N<sub>3</sub>, NH<sub>2</sub>, NO<sub>2</sub>, CN, COOH, COOA, CONH<sub>2</sub>, CONHA, CON(A)<sub>2</sub>, O-allyl, O-propargyl, O-benzyl, =N-OH, =N-OA or =CF<sub>2</sub>,

R<sup>2</sup> denotes H or A,

Ph denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by A, OA, OH or Hal,

R<sup>3</sup> denotes H, Hal or A,

 $R^4$  denotes  $-C_6H_4-(CH_2)_n-NR^5R^{5'}$ ,  $-C(=NR^5)NR^5R^{5'}$ ,

$$\{ \begin{array}{c} (CH_2)_n\text{-NR}^5R^5 \\ \\ N \end{array} \quad \text{or} \quad \begin{cases} \begin{array}{c} N \\ \\ N \end{array} \\ \\ R^5 \end{array}$$

R<sup>5</sup>, R<sup>5'</sup> each, independently of one another, denote H or A,

A denotes unbranched, branched or cyclic alkyl having 1-12 C atoms, in which, in addition, 1-7 H atoms may be replaced by F and/or chlorine,

Hal denotes F, Cl, Br or I,

n denotes 0, 1, 2 or 3,

according to Claim 1 and or pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, characterised in that comprising reacting

a) a compound of the formula II

$$R \longrightarrow NH_2$$
 II

in which R has the meaning indicated in Claim 1,

is reacted with a chloroformate derivative to give an intermediate carbamate derivative,

which is subsequently reacted reacting said intermediate with a compound of the formula III

$$\begin{array}{c|c}
R^1 \\
R^2 \\
N \\
N \\
O \\
R^3
\end{array}$$
|||

in which

R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> have the meaning indicated in Claim 1,

or

b) reacting a compound of the formula III

is reacted with a compound of the formula IV

$$R - N = C = O$$
 IV

in which

R has the meaning indicated in Claim 1,

or

# c) reacting a compound of the formula V

$$H_2N$$
 $R^4$ 
 $V$ 

in which R<sup>3</sup> and R<sup>4</sup> have the meaning indicated in Claim 1,

## is reacted with a compound of the formula VI

$$\begin{array}{c|c} R & & & \\ & & & \\ R & & & \\ & & & \\ N & & O \end{array} \qquad VI$$

in which

L denotes Cl, Br, I or a free or reactively functionally modified OH group and

R, R<sup>+</sup> and R<sup>2</sup> have the meanings indicated in Claim 1,

### and/or converting

a base or acid of the formula I is converted into one of its salts.

## 10. (Currently Amended) Compounds of the formula Laccording to Claim Las

inhibitors A method of coagulation factor Xa, comprising administering to a host in need thereof a compound of claim 8 or a pharmaceutically useable derivative, salt or stereoisomer thereof.

- 11. (Canceled).
- 12. (Currently Amended) Medicaments A pharmaceutical composition comprising at least one compound of the formula I according to Claim 1 and/or pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios, and optionally pharmaceutically acceptable excipients and/or adjuvants.
- 13. (Canceled).
- 14. (Previously Presented) Use of compounds according to Claim 1-and/or physiologically acceptable salts and solvates thereof for the preparation of a medicamentA method for the treatment of thromboses, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, tinnitus, tumours, tumour diseases and/or tumour metastases, comprising administering to a host in need thereof an effective amount of a compound of claim 8 and/or pharmaceutically useable derivatives, salts or stereoisomers thereof.
- 15. (Previously Presented) Set (kit) consisting of separate packs of
  - (a) an effective amount of a compound of the formula I according to Claim 1 and/or pharmaceutically usable derivatives, solvates, salts and stereo-isomers thereof, including mixtures thereof in all ratios,

and

(b) an effective amount of a further medicament active ingredient.

16. (Canceled).